Pacira BioSciences, Inc.
PCRXNASDAQHealthcare● Active
$22.86
+$0.11(+0.48%)
Market Cap$899198100
P/E Ratio—
52W High$27.64
52W Low$18.8
Pacira BioSciences, Inc. (PCRX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PCRX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.01B | ($0.10B) | $0.04B | $0.02B | $0.04B |
| Depreciation & Amort. | $0.09B | $0.08B | $0.08B | $0.09B | $0.03B |
| Stock-Based Comp. | $0.06B | $0.05B | $0.05B | $0.05B | $0.04B |
| Change in Working Capital | ($0.04B) | ($0.02B) | ($0.05B) | ($0.02B) | ($0.02B) |
| Net Cash from Operations | $0.15B | $0.19B | $0.15B | $0.15B | $0.13B |
| Investing Activities | |||||
| Capital Expenditure | ($0.02B) | ($0.01B) | ($0.02B) | ($0.03B) | ($0.05B) |
| Purchases of Investments | ($0.14B) | ($0.25B) | ($0.14B) | ($0.40B) | ($0.63B) |
| Sales of Investments | $0.27B | $0.18B | $0.24B | $0.24B | $1.08B |
| Net Cash from Investing | $0.10B | ($0.08B) | $0.08B | ($0.23B) | ($0.02B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.15B) | ($0.03B) | ($0.00B) | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.22B) | $0.08B | ($0.18B) | ($0.43B) | $0.36B |
| Net Cash from Financing | ($0.37B) | $0.02B | ($0.18B) | ($0.40B) | $0.38B |
| Free Cash Flow | |||||
| Free Cash Flow | $0.14B | $0.18B | $0.14B | $0.12B | $0.08B |
| FCF Margin %(computed) | 18.81% | 25.50% | 20.67% | 17.28% | 14.75% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Pacira BioSciences, Inc. data
About Pacira BioSciences, Inc. (PCRX) Cash Flow Statement
Pacira BioSciences, Inc. generated operating cash flow of $0.15B and free cash flow of $0.14B for 2025 — a FCF margin of 18.81%. Capital expenditure was ($0.02B).
Frequently asked questions
PCRX · 4 questionsPacira BioSciences, Inc. generated free cash flow of $0.14B for 2025, down 23.5% year-over-year.
PCRX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10